6:04 PM
 | 
Apr 25, 2013
 |  BC Extra  |  Company News

Pfizer says negative CHMP opinion for Xeljanz

Pfizer Inc. (NYSE:PFE) said EMA's CHMP recommended against approval of an MAA for Xeljanz tofacitinib to treat moderate to severe rheumatoid arthritis. According to Pfizer, the committee said that while Xeljanz improved the signs and symptoms of RA...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >